MAT Tools and Resources

This fact sheet includes basic descriptions of medications for opioid use disorders (MOUD) including naltrexone, buprenorphine, and methadone. It also addresses how MOUD can help those struggling with opioid use disorder, misunderstandings about MOUD, and additional considerations.

This fact sheet includes a basic description of opioids, a brief explanation of the risks, ways to prevent misuse, and strategies to helped loved ones who may be struggling with substance use disorder.

This fact sheet includes a basic description of stimulants, a brief explanation of the risks, ways to prevent misuse, and strategies to helped loved ones who may be struggling with substance use disorder.

This fact sheet includes a basic description of fentanyl, a brief explanation of the danger, and strategies to helped loved ones who may be using or at risk of using fentanyl.

This web page provides frequently asked questions for rules on prescribing buprenorphine and other and other medications for opioid use disorder (MOUD), following 2023 policy updates.

This web page provides frequently asked questions regarding the 2023 Medication Access and Training Expansion (MATE) Act which requires new or renewing DEA licensees to have completed a total of at least eight hours of training on opioid or other substance use disorders and the appropriate treatment of pain.

This letter announces details on the 2023 Medication Access and Training Expansion (MATE) Act which requires new or renewing DEA licensees to have completed a total of at least eight hours of training on opioid or other substance use disorders and the appropriate treatment of pain.

This web page provides frequently asked questions regarding the 2023 Consolidated Appropriations Act, which eliminates the X-waiver (DATA-Waiver) and increases accessibility of medication-assisted treatment (MAT).

This guidance document provides information regarding issuance of updated DEA registration certificates to reflect Congress’s elimination of the X-waiver (DATA-Waiver) in the Consolidated Appropriations Act of 2023, increasing accessibility of medication-assisted treatment (MAT).

This letter announces details on Congress's elimination of the X-waiver (DATA-Waiver) to increase buprenorphine accessibility in the Consolidated Appropriations Act of 2023, increasing accessibility of medication-assisted treatment (MAT).